Status:
UNKNOWN
Efficacy Study of Cilostazol Loading in Elective Percutaneous Coronary Intervention
Lead Sponsor:
Samsung Medical Center
Conditions:
Angioplasty, Transluminal, Percutaneous Coronary
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
The purpose of this study is to investigate the effect of cilostazol loading before planned PCI on major adverse cardiac and cerebrovascular events in patients with coronary artery disease.
Eligibility Criteria
Inclusion
- Patients undergoing elective PCI
- Presence of coronary lesions amenable to stent
Exclusion
- Cardiogenic shock
- Urgent PCI
- Hypersensitivity to aspirin, clopidogrel, or cilostazol
- LVEF \< 30% or congestive heart failure
- Bleeding diathesis
- leukocyte count \< 3,000/mm3 and/or platelet count \< 100,000/mm3
- aspartate aminotransferase or alanine aminotransferase \> 3 times upper normal; serum creatinine \> 2.0 mg/dl
- noncardiac disease with a life expectancy \< 1 year
- inability to follow the protocol
Key Trial Info
Start Date :
July 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2011
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT00938522
Start Date
July 1 2009
End Date
October 1 2011
Last Update
July 21 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samsung Medical Center
Seoul, South Korea, 135-710